Orexin-A vs hGHRH(1-40)OH
Head-to-head comparison of Orexin-A (Hypocretin-1 (Orexin-A)) and hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Orexin-A | hGHRH(1-40)OH |
|---|---|---|
| Category | Cognitive Enhancement | Growth Hormone |
| Full Name | Hypocretin-1 (Orexin-A) | Human growth hormone-releasing factor (1-40) hydroxyl |
| Molecular Weight | 3562 Da | N/A |
| Half-Life | Minutes to <1 hour | 5-20 minutes |
| Amino Acids | 33 | 40 |
| Typical Dose | Research-only; no validated human dose | 1-2 mcg/kg |
| Route | Intracerebroventricular/Intranasal | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 42 | 85 |
| Research Status | Pre-clinical | Clinical Research |
Orexin-A Benefits
- ✓wakefulness
- ✓attention
- ✓memory consolidation
- ✓fatigue resistance
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
Orexin-A Dosing
Research-only i.c.v. microgram/nanomolar studies|intranasal experimental use|no established human protocol
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
Orexin-A Side Effects
- ⚠insomnia
- ⚠headache
- ⚠blood pressure changes
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Research Overview
Orexin-A
Preclinical studies link orexin signaling to arousal, learning, and memory consolidation, making orexin-A a candidate for cognition-related research. It is not an approved cognitive enhancer and remains an experimental peptide.
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.